<DOC>
	<DOCNO>NCT02640729</DOCNO>
	<brief_summary>This study seek evaluate safety efficacy Nelotanserin treatment visual hallucination subject Lewy body dementia .</brief_summary>
	<brief_title>Study Evaluating Nelotanserin Treatment Visual Hallucinations Subjects With Lewy Body Dementia</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , cross-over study subject Lewy body dementia experience frequent visual hallucination . Subjects meet randomization criterion enter double-blind treatment period . Each subject randomize 1:1 one 2 treatment sequence : Nelotanserin first treatment period follow placebo second treatment period , placebo first treatment period follow Nelotanserin second treatment period .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Hallucinations</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Adult subject age 5085 , inclusive , diagnosis LBD base DSM5 diagnostic criterion diagnosis Parkinson 's disease dementia ( PDD ) base DSM5 diagnostic criterion ; Presence frequent visual hallucination Mini Mental State Examination score â‰¥ 18 Subjects current diagnosis significant psychotic disorder include , limited , schizophrenia bipolar disorder Subjects ' psychotic symptom secondary well account another medical condition , psychiatric disorder , substance abuse Subjects current serious and/or unstable cardiovascular , respiratory , thyroid , gastrointestinal , renal , hematologic medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lewy body dementia</keyword>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Parkinson 's disease dementia</keyword>
	<keyword>Lewy body</keyword>
	<keyword>Visual hallucination</keyword>
</DOC>